The role of the microbiome in NAFLD and NASH

Abstract Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic stea...

Full description

Bibliographic Details
Published in:	EMBO Molecular Medicine
Main Authors:	Aleksandra A Kolodziejczyk, Danping Zheng, Oren Shibolet, Eran Elinav
Format:	Article
Language:	English
Published:	Springer Nature 2018-12-01
Subjects:	microbiome/microbiota nonalcoholic fatty liver disease nonalcoholic steatohepatitis
Online Access:	https://doi.org/10.15252/emmm.201809302

Similar Items

Noninvasive Diagnosis of NAFLD and NASH
by: Valeria Annarita Piazzolla, et al.
Published: (2020-04-01)

Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
by: Ankoor H. Patel, et al.
Published: (2024-07-01)

Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
by: Marielle Malucelli, et al.
Published: (2023-11-01)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH
by: Meenakshi Vachher, et al.
Published: (2022-10-01)

An Update on the Chemokine System in the Development of NAFLD
by: Naoto Nagata, et al.
Published: (2022-06-01)

Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
by: Man Wang, et al.
Published: (2022-10-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
by: Wasitha P. D. W. Thilakarathna, et al.
Published: (2024-02-01)

An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients
by: Pathik Parikh, et al.
Published: (2016-01-01)

Association between triglyceride-glucose related indices and at-risk NASH in U.S. adults with NAFLD: results from NHANES 2017-2020
by: Hanchen Ma, et al.
Published: (2025-06-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
by: Lucia Carulli, et al.
Published: (2019-02-01)

Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study
by: Yu Zhang, et al.
Published: (2020-06-01)

Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S]
by: D.Lee Gorden, et al.
Published: (2015-03-01)

Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways
by: Glenn S. Gerhard, et al.
Published: (2018-07-01)

Peripheral immune cells in NAFLD patients: A spyhole to disease progression
by: Shuang-Zhe Lin, et al.
Published: (2022-01-01)

Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)
by: Naveen Kalra, et al.
Published: (2009-01-01)

Unraveling Hepatic Metabolomic Profiles and Morphological Outcomes in a Hybrid Model of NASH in Different Mouse Strains
by: Gabriel P. Bacil, et al.
Published: (2023-01-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact
by: David Højland Ipsen, et al.
Published: (2021-01-01)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Ji-Young Cha, et al.
Published: (2018-12-01)

Comparison of liver enzymes level and sonographic findings value with liver biopsy findings in nonalcoholic fatty liver disease patients
by: Mahsa Khodadoostan, et al.
Published: (2016-01-01)

A significant and persistent rise in the global burden of adolescent NAFLD and NASH estimated by BMI
by: Xiao-Yun Lin, et al.
Published: (2024-10-01)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl<sub>4</sub>-Induced NASH Mice and the Effect of Obeticholic Acid
by: Nanlin Zhu, et al.
Published: (2021-06-01)

ADEMETHIONINE IN THERAPY OF NON-ALCOHOLIC FATTY LIVER DISEASE
by: A. V. Polukhina, et al.
Published: (2017-11-01)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
by: Eleftheria Galatou, et al.
Published: (2022-05-01)

Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation
by: Julie Hviid Klaebel, et al.
Published: (2020-09-01)

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
by: Mohamed Salaheldin, et al.
Published: (2023-08-01)

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by: Reeju Amatya, et al.
Published: (2023-07-01)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
by: Margaret LP Teng, et al.
Published: (2023-04-01)

Association of vitamin D supplementation with serum leptin and metabolic parameters in Egyptian patients with non-alcoholic steatohepatitis: a prospective study
by: Hany Haroun Kaisar, et al.
Published: (2020-08-01)

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
by: Umair Iqbal, et al.
Published: (2019-03-01)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
by: Alexandra C. Finney, et al.
Published: (2023-05-01)

The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease
by: Mary Barbara, et al.
Published: (2021-09-01)

Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota
by: Shuying He, et al.
Published: (2022-04-01)

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
by: Imke Liebold, et al.
Published: (2023-01-01)

Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients
by: Adrian T. Billeter, et al.
Published: (2021-08-01)

Naringenin attenuates early hepatocarcinogenesis induced by a MASH model
by: Linda Vanessa Márquez-Quiroga, et al.
Published: (2025-07-01)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
by: Akiko Sakasai-Sakai, et al.
Published: (2023-03-01)